Today, at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (GU) held at Moscone West in San Francisco, CA, Nektar (NKTR) will present preliminary efficacy, safety and immune monitoring data from the ongoing metastatic urothelial carcinoma (mUC) patient cohort in the PIVOT-02 study evaluating NKTR-214 in combination with Bristol-Myers immunotherapy product OPDIVO (nivolumab).
NKTR-214 is a CD122-biased agonist designed to provide sustained signaling through the IL-2 βγ receptor.

PIVOT-02 is an ongoing study of NKTR-214 + nivolumab in patients with . . .